QR-koodi

Prospective Trial on the Pharmacokinetics of Clopidogrel in Hemodialysis Patients

Introduction: Hemodialysis patients (HDPs) exhibit extensive cardiovascular risk. The widely prescribed anti-platelet agent clopidogrel is metabolically activated by cytochrome enzymes, which may be impaired by uremia and chronic low-grade inflammation, typically present in HDPs. We conducted a pros...

Täydet tiedot

Tallennettuna:
Päätekijät: Juergen Grafeneder, Wisse van Os, Iris K. Minichmayr, Katarina D. Kovacevic Miljevic, Birgit Reiter, Marcus D. Säemann, Veronika Machold-Fabrizii, Amro Ahmed, Paul Spechtl, Haris Omic, Raute Sunder-Plaßmann, Bernd Jilma, Christian Schoergenhofer, Farsad Eskandary
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Elsevier 2024-10-01
Sarja:Kidney International Reports
Aiheet:
cardiovascular risk
clopidogrel
cytochrome P450
hemodialysis
pharmacokinetics
platelet aggregation
Linkit:http://www.sciencedirect.com/science/article/pii/S246802492401859X
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia